Shinbon Pharmaceutical announced today that three drugs, including breviscapine dripping pills, have received drug registration approvals and clinical approvals, respectively. According to the announcement, Breviscapine Dripping Pills recently received a registration document for the registration of drugs issued by the State Food and Drug Administration. The medicine has the functions of promoting blood circulation, removing blood stasis, and relieving pain and pain. It is used to treat stroke sequelae, coronary heart disease and angina pectoris and can greatly improve the dissolution and absorption of drugs, thereby increasing its bioavailability, especially for patients with inconvenient swallowing. . In addition, the new drug omeprazole capsules, febuxostat raw materials and tablets jointly developed by the company and Beijing Rundekang Pharmaceuticals were recently approved by the State Food and Drug Administration for clinical trials of drugs, and the two new drugs will enter clinical practice. Experimental research phase. Omeprazole capsules are used for the treatment of hyperacidity, gastroesophageal reflux disease, erosive esophagitis, benign active gastric ulcers, active duodenal ulcers, and the maintenance of corrosive esophagitis; Bustastat is used for the treatment of chronic uric acid that has already formed in uric acid deposition. Xinbang Pharmaceutical stated that the approved production and clinical trials of these drugs will have a positive impact on the company's future performance. However, the specific sales situation and clinical trial research are affected by many factors, there is a certain degree of uncertainty. Wheel Loader,Small Wheel Loader,Mini Wheel Loaders,Front End Wheel Loader Taian zhengtai construction machinery Co., Ltd , https://www.taztmachine.com